Moreover, chronic treatment with pirfenidone inhibited angiotensin II and DOCA salt-induced cardiac hypertrophy and fibrosis (Mirkovic et al., 2002; Yamazaki et al., 2012), and in diabetic db/db mice, pirfenidone treatment inhibited mesangial cell proliferation and interstitial collagen formation, though without changing albuminuria (RamachandraRao et al., 2009). The gene discussed is AGT; the disease is cardiac hypertrophy.